Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.140
-0.060 (-5.00%)
Feb 27, 2026, 4:00 PM EST - Market closed

Rein Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
305015115142
Market Cap Growth
-39.83%234.56%38.39%-78.89%20.50%165.52%
Enterprise Value
26773-15-133
Last Close Price
1.142.303.052.3711.2620.80
PB Ratio
24.190.920.150.581.163.48
P/TBV Ratio
---0.581.163.48
Debt / Equity Ratio
--00.000.000.03
Net Debt / Equity Ratio
-0.09-0.24-0.18-1.14-1.04-1.10
Net Debt / EBITDA Ratio
0.170.461.130.771.730.66
Net Debt / FCF Ratio
0.190.580.870.851.910.66
Quick Ratio
0.712.243.956.2810.193.49
Current Ratio
0.902.384.176.4610.694.12
Return on Equity (ROE)
-83.28%-82.37%-26.91%-87.41%-93.33%-150.00%
Return on Assets (ROA)
-18.81%-20.89%-14.99%-49.03%-51.30%-59.84%
Return on Capital Employed (ROCE)
-49.60%-49.80%-15.10%-148.50%-60.50%-165.50%
Earnings Yield
-196.50%-126.19%-105.62%-253.93%-51.32%-50.00%
FCF Yield
-69.92%-44.73%-132.99%-231.03%-46.90%-48.41%
Buyback Yield / Dilution
-71.80%-290.09%-1.31%-2.23%-154.70%-42.11%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q